相关实验视频
Updated: Jul 25, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
在风湿性疾病中JAK抑制剂的新兴安全概况
Jasvinder A Singh1,2,3
1Medicine Service, VA Medical Center, 700 19th St S, Birmingham, AL, 35233, USA. Jasvinder.md@gmail.com.
概括
雅努斯激酶抑制剂 (JAKi) 为风湿性疾病的生物疗法提供了口服替代品. 最近的FDA警告强调了与JAKi相关的心血管和癌症风险,需要对其比较安全性进行审查.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 简氏激酶抑制剂 (JAKi) 是一种口服小分子药物,向细胞内信号传导.
- 批准用于类风湿性关节炎等类风湿性疾病,JAKi作为可注射生物疗法的替代品.
- 最近的安全数据将JAKi与瘤亡因子抑制剂 (TNFi) 进行比较,促使FDA发出黑子警告.
研究的目的:
- 审查有关JAK抑制剂在风湿性疾病中的安全性的当前数据.
- 分析JAKi药物之间的风险差异以及各种适应症的风险差异.
- 为了确定与JAKi治疗相关的不良结果的风险因素.
主要方法:
- 对JAK抑制剂安全性发表的文献进行系统审查.
- 对JAKi和瘤亡因子抑制剂 (TNFi) 之间的安全数据的比较分析.
- 在使用JAKi的患者中检查心血管和癌症事件的危险因素.
主要成果:
- 美国食品和药物管理局针对JAKi发布了关于心血管和癌症风险的新黑警告.
- 基于新出现的安全数据,针对JAK抑制剂实施了标签变化.
- 讨论了JAKi药物之间的安全性概况的差异以及各种适应症的差异.
结论:
- 与传统的生物疗法相比,JAK抑制剂存在明显的安全问题.
- 了解比较安全性和风险因素对于优化JAKi在类风湿性疾病中的使用至关重要.
- 需要持续的警和进一步的研究,以充分阐明JAKi的安全概况.
更多相关视频
相关概念视频
01:20The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
01:23Rheumatic Heart Disease I: Introduction
17
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
17
01:21Rheumatic Heart Disease III: Medical Management
22
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
22
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
38
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
38
01:20Rheumatic Heart Disease IV: Nursing Management
23
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
23
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177